La biotech liégeoise Amyl Therapeuticslève 8 millions pour attaquer Alzheimer

Amyl Therapeutics secures €8.25M Series A extension to validate novel neurodegenerative disease platform.

AD/PD 2026 – A Great Success for Amyl Therapeutics !

A symbolic milestone reached in our laboratory !

Upcoming conferences

2025 – A pivotal year for Amyl

PEGS Europe – Lisbon 2025

New Horizons in Neurodegeneration – Leuven 2025

Amyl Therapeutics is part of the Mediaplanet’s Life Sciences campaign

La biotech liégeoise Amyl Therapeutics ouvre une nouvelle voie contre l’Alzheimer

World Alzheimer’s Day

BIO International Convention – Boston 2025

Team Building Event 2025

LSX Nordic Congress 2025

Swiss Biotech Day 2025 – Amyl, one of the nine startups selected to pitch

LSX World Congress 2025

Amyl Therapeutics – One of the ten startups selected to pitch at BioVaria